Diligence memo · auto-generated · as of July 2, 2026
Swift Biosciences, Inc.
Swift Biosciences, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Swift Biosciences, Inc. operates in Biotech / Pharma, based in ANN ARBOR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Swift Biosciences, Inc. has raised $31M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2017-05-31.
Most recent recorded round closed around 2018-11-01.
Valuation (modeled)modeled
Provath models Swift Biosciences, Inc. at approximately $134M (range $4.5M–$729M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Series A Biotech / Pharma companies in 2016–2018 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 7.7 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 84% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Oncoheroes Biosciences Inc., Pharmaca Integrative Pharmacy Inc, PharmacoPhotonics, Inc., Key Biologics Holdings, LLC.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.